{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:51:45Z","timestamp":1768553505050,"version":"3.49.0"},"posted":{"date-parts":[[2022,4,10]]},"group-title":"Hematology","reference-count":37,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immunocompromised patients, including those with haematological malignancies, are among the high-risk group to develop severe coronavirus disease 2019 (COVID-19) complications. The effectiveness of passive immunotherapy with convalescent plasma (CP) on such patients diagnosed with COVID-19 has not been reviewed. Therefore, the aim of this review was to systematically appraise the current evidence for the efficacy of this therapy in haematological malignancies patients with COVID-19 infection.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A comprehensive search was conducted up-to October 2021, using four databases: PubMed, Web of Science, Science Direct, and Scopus. Two reviewers independently assessed the quality of the included studies. Data collection analysis were performed using Microsoft Excel 365 and GraphPad Prism software.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>17 studies met the inclusion criteria; these records included 258 COVID-19 patients with haematological malignancies and treated with CP therapy (CPT). The main findings from the reviewed data suggests CPT may be associated with improved clinical outcomes including (a) higher survival rate, (b) improved SARS-CoV-2 clearance and presence of detectable anti-SARS-CoV-2 antibodies post CP transfusion, (c) improved hospital discharge time, and recovery after 1 month of CP therapy. Furthermore, treatment with convalescent plasma was not associated with development of adverse events.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Owing to its safety and beneficial effects in improving clinical outcomes, CPT appears to be an effective supportive therapeutic option for haematological malignancy patients infected with COVID-19.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2022.04.06.22273542","type":"posted-content","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T01:50:19Z","timestamp":1649641819000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of convalescent plasma therapy in COVID-19 patients with haematological malignancies"],"prefix":"10.64898","author":[{"given":"Sapha","family":"Shibeeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilham","family":"Ajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"Al-Jighefee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atiyeh","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"7803","key":"2022041211200772000_2022.04.06.22273542v1.1","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author Correction: A new coronavirus associated with human respiratory disease in China","volume":"580","year":"2020","journal-title":"Nature"},{"issue":"3","key":"2022041211200772000_2022.04.06.22273542v1.2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.tracli.2021.04.004","article-title":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","volume":"28","year":"2021","journal-title":"Transfus Clin Biol"},{"issue":"3","key":"2022041211200772000_2022.04.06.22273542v1.3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12250-020-00207-4","article-title":"Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools","volume":"35","year":"2020","journal-title":"Virol Sin"},{"issue":"11","key":"2022041211200772000_2022.04.06.22273542v1.4","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1111\/ajt.16133","article-title":"Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation","volume":"20","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"10241","key":"2022041211200772000_2022.04.06.22273542v1.5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"2022041211200772000_2022.04.06.22273542v1.6","doi-asserted-by":"crossref","first-page":"102956","DOI":"10.1016\/j.transci.2020.102956","article-title":"Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia","volume":"60","year":"2021","journal-title":"Transfus Apher Sci"},{"issue":"22","key":"2022041211200772000_2022.04.06.22273542v1.7","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1002\/cam4.3457","article-title":"Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients","volume":"9","year":"2020","journal-title":"Cancer Med"},{"issue":"2","key":"2022041211200772000_2022.04.06.22273542v1.8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic","volume":"26","year":"2021","journal-title":"Drug Discovery Today"},{"key":"2022041211200772000_2022.04.06.22273542v1.9","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.045120"},{"key":"2022041211200772000_2022.04.06.22273542v1.10","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002888"},{"issue":"1","key":"2022041211200772000_2022.04.06.22273542v1.11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12015-020-10107-5","article-title":"Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient","volume":"17","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"2022041211200772000_2022.04.06.22273542v1.12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clml.2020.06.012","article-title":"Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma","volume":"21","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2022041211200772000_2022.04.06.22273542v1.13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19","volume":"7","year":"2021","journal-title":"JAMA Oncology"},{"key":"2022041211200772000_2022.04.06.22273542v1.14","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2020002595"},{"key":"2022041211200772000_2022.04.06.22273542v1.15","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.927812"},{"key":"2022041211200772000_2022.04.06.22273542v1.16","doi-asserted-by":"crossref","unstructured":"Malsy J , Veletzky L , Heide J , Hennigs A , Gil-Ibanez I , Stein A , et al. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19. Clin Infect Dis. 2020.","DOI":"10.1093\/cid\/ciaa1637"},{"issue":"1","key":"2022041211200772000_2022.04.06.22273542v1.17","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.transci.2020.102983","article-title":"SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation","volume":"60","year":"2021","journal-title":"Transfusion and Apheresis Science"},{"key":"2022041211200772000_2022.04.06.22273542v1.18","doi-asserted-by":"crossref","unstructured":"Biernat MM , Kolasi\u0144ska A , Kwiatkowski J , Urbaniak-Kujda D , Biernat P , Janocha-Litwin J , et al. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. Viruses. 2021;13(3).","DOI":"10.3390\/v13030436"},{"issue":"5","key":"2022041211200772000_2022.04.06.22273542v1.19","doi-asserted-by":"crossref","first-page":"102821","DOI":"10.1016\/j.transci.2020.102821","article-title":"Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis","volume":"59","year":"2020","journal-title":"Transfusion and Apheresis Science"},{"key":"2022041211200772000_2022.04.06.22273542v1.20","doi-asserted-by":"crossref","unstructured":"Dell\u2019Isola GB , Felicioni M , Ferraro L , Capolsini I , Cerri C , Gurdo G , et al. Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection. Frontiers in Pediatrics. 2021;9(777).","DOI":"10.3389\/fped.2021.712603"},{"issue":"6","key":"2022041211200772000_2022.04.06.22273542v1.21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","article-title":"Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies","volume":"62","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2022041211200772000_2022.04.06.22273542v1.22","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2022041211200772000_2022.04.06.22273542v1.23","doi-asserted-by":"crossref","first-page":"103075","DOI":"10.1016\/j.transci.2021.103075","article-title":"Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies","volume":"60","year":"2021","journal-title":"Transfusion and Apheresis Science"},{"issue":"5","key":"2022041211200772000_2022.04.06.22273542v1.24","doi-asserted-by":"crossref","first-page":"102871","DOI":"10.1016\/j.transci.2020.102871","article-title":"Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma","volume":"59","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"2022041211200772000_2022.04.06.22273542v1.25","doi-asserted-by":"crossref","first-page":"102525","DOI":"10.1016\/j.bcmd.2020.102525","article-title":"Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies","volume":"87","year":"2021","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"8","key":"2022041211200772000_2022.04.06.22273542v1.26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19","volume":"7","year":"2021","journal-title":"JAMA Oncology"},{"key":"2022041211200772000_2022.04.06.22273542v1.27","doi-asserted-by":"crossref","unstructured":"Biernat MM , Kolasinska A , Kwiatkowski J , Urbaniak-Kujda D , Biernat P , Janocha-Litwin J , et al. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. VIRUSES-BASEL. 2021;13(3).","DOI":"10.3390\/v13030436"},{"key":"2022041211200772000_2022.04.06.22273542v1.28","doi-asserted-by":"crossref","unstructured":"Wardhani SO , Fajar JK , Wulandari L , Soegiarto G , Purnamasari Y , Asmiragani A , et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: A meta-analysis. F1000Research. 2021;10.","DOI":"10.12688\/f1000research.36396.3"},{"key":"2022041211200772000_2022.04.06.22273542v1.29","doi-asserted-by":"crossref","unstructured":"Abelda\u00f1o Zu\u00f1iga RA , Coca SM , Abelda\u00f1o GF , Gonz\u00e1lez-Villoria RAM. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis. Therapeutic Advances in Respiratory Disease. 2021;15.","DOI":"10.1177\/17534666211007214"},{"issue":"2","key":"2022041211200772000_2022.04.06.22273542v1.30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/jmv.26408","article-title":"Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis","volume":"93","year":"2021","journal-title":"Journal of Medical Virology"},{"issue":"5","key":"2022041211200772000_2022.04.06.22273542v1.31","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5114\/aoms\/132492","article-title":"Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis","volume":"17","year":"2021","journal-title":"Arch Med Sci"},{"key":"2022041211200772000_2022.04.06.22273542v1.32","first-page":"378","article-title":"Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis","volume":"8","year":"2021","journal-title":"Frontiers in Medicine"},{"key":"2022041211200772000_2022.04.06.22273542v1.33","doi-asserted-by":"crossref","unstructured":"Valk SJ , Piechotta V , Kimber C , Chai KL , Monsef I , Doree C , et al. Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2. Cochrane Database of Systematic Reviews. 2021;2020(12).","DOI":"10.1002\/14651858.CD013802"},{"issue":"3","key":"2022041211200772000_2022.04.06.22273542v1.34","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.tracli.2021.04.004","article-title":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","volume":"28","year":"2021","journal-title":"Transfusion Clinique et Biologique"},{"key":"2022041211200772000_2022.04.06.22273542v1.35","unstructured":"Bloch EM . COVID-19: Convalescent plasma and hyperimmune globulin. In: Kleinman S , Tirnauer JS , Feldweg TM , editors. UpToDate, Waltham, MA. 2021."},{"key":"2022041211200772000_2022.04.06.22273542v1.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"2022041211200772000_2022.04.06.22273542v1.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.04.06.22273542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:41:02Z","timestamp":1768488062000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.04.06.22273542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,10]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1101\/2022.04.06.22273542","relation":{},"subject":[],"published":{"date-parts":[[2022,4,10]]},"subtype":"preprint"}}